Navigation Links
Next-generation Targeted Cytokine Therapy to be Explored on Advancements Series

An upcoming episode of Advancements with Ted Danson, scheduled to broadcast 2Q/2020, will explore innovative treatment solutions for maladies, such as Inflammatory Bowel Disease (IBD), specifically Crohn’s Disease (Crohn’s), and Oncology. Check local listings for more info.

This segment will focus on a novel platform developed by Deka Biosciences, Inc. (Deka Biosciences), that will enable the delivery of next generation cytokine or combination of cytokines to a specific tissue of interest. Viewers will learn how this cutting-edge technology, termed Diakines™, has led to the development of two potential therapeutic molecules involving an affinity modified Interleukin 10 cytokine.

The show will also explore how Deka Biosciences is using Diakines™ to harness the spectrum of therapeutically useful and clinically validated IL10 and other cytokine specific biologies. Spectators will see how these Diakines™ can maximize patient benefits through improved PK/PD function combined with a MOA directed patient selection strategy.

“The biopharma industry has known for a while that cytokines play an integral role in immunology and disease management, and that delivery of cytokine therapeutics into diseased tissues will dramatically enhance therapeutic benefit,” said Dr. John Mumm, co-founder & CEO of Deka Biosciences. He continued to say, “Deka Biosciences has harnessed the wealth of clinical knowledge around cytokines and IL-10 in particular, to develop a novel delivery platform to enrich cytokine variants in effected tissues, coupled with methods to determine how to select the patients with the greatest likelihood of response to ensure that the right patients get the right medicines.”

In addition, the show will also inform about Deka Biosciences’ Precision Medicine strategy, which enables Deka to identify the right patients to treat with these new medicines.

“Deka’s platform has the potential to enable discoveries of next generation therapies,” said Richard Lubin, senior producer for DMG Productions and the Advancements series. “We are eager to explore how Deka is set to influence future treatment options for IBD, Crohn’s.”

About Deka Biosciences:
Deka BioSciences, Inc., is an early-stage biotech focused on creating the next generation targeted cytokine therapies to treat chronic illnesses such as Crohn’s Disease and Oncology. Deka’s focus is on the development of optimized disease specific IL-10 variants coupled with the DiakinesTM T1/2 life extension tissue targeting technology. In parallel, Deka has developed a Precision Medicine strategy by identifying the genetic signature that drives responses to treatment to enable the selection of the patients most likely to benefit from our therapies.

About Advancements and DMG Productions:
The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today’s consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world.

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming on which both viewers and networks depend.

For more information, please visit or call Richard Lubin at 866-496-4065.

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology news :

1. Octapharma Adopts Genedata Bioprocess to Develop Next-generation Bio-manufacturing Processes
2. Next-Generation VYPR 2 Horticulture Solution Ensures High-Yield, Consistent Harvests in Every Season
3. Next-Generation Biologics: R&D, Industry and Market Forecasts 2015-2025
4. PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis
5. Researcher using next-generation sequencing to rapidly identify pathogens
6. Scientists successfully generate human platelets using next-generation bioreactor
7. Lawrence Livermore Lab awarded $5.6 million to develop next-generation neural devices
8. Next-generation glaucoma therapeutics hold considerable promise
9. CHOP introduces HLA typing by next-generation sequencing to its clinical services
10. Sanford-Burnham receives US Air Force grant to perform next-generation toxicity screens
11. Allen Institute for Brain Science partners with imec for development of next-generation tools
Post Your Comments:
(Date:5/1/2020)... ... 01, 2020 , ... More than 600 people undergo genetic counseling and testing ... is led by two genetic counselors. , My Gene Counsel , a digital ... with UConn’s High Rick Program to ensure that UConn’s patients who have undergone genetic ...
(Date:4/26/2020)... , ... April 23, 2020 , ... ... in computer miniaturization, backed by FII Tech Growth managed by Fondo Italiano d’Investimento ... the biomedical market, for the development of Respira, a new non-invasive pulmonary ventilator ...
(Date:4/22/2020)... ... April 21, 2020 , ... ... and innovation in technology and compliance, announces a new managed service to improve ... of alliances – Box, ComplianceQuest, and USDM Life Sciences (USDM) – Unify Compliance ...
Breaking Biology News(10 mins):
(Date:5/9/2020)... ANGELES (PRWEB) , ... May 08, 2020 , ... ... episode of their successful business program on Sunday, May 10, 2020 and Wednesday, May ... U.S. coast! This episode’s exclusive interviews will spotlight key executives from Techolution ...
(Date:5/5/2020)... ... 2020 , ... Smart Meter, a diabetes management ... LTE Cat-M Cellular Connected Diabetes Blood Glucose Monitor and Remote Patient Monitoring ... broadest cellular connectivity available, to provide patients with seamless connectivity to their physicians ...
(Date:4/23/2020)... ... April 22, 2020 , ... ... providers to protect themselves from COVID-19. Virginia has only been receiving 50% to ... Management Association (FEMA). , As Governor Northam told the Virginia Mercury, “While we ...
(Date:4/22/2020)... Mich. (PRWEB) , ... April 21, 2020 , ... ... researchers continue their work through COVID-19. Many clinical trial teams are working remotely ... online. Ripple Science wants to help researchers continue their research during this uncertain ...
Breaking Biology Technology: